Remove BioTech Remove Digital Health Remove Drug Development Remove Pharmaceuticals
article thumbnail

Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson’s Disease

Digital Health Global

BASEL, Switzerland–(BUSINESS WIRE)–Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson’s disease.

article thumbnail

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Digital Health Global

About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation. About ClavystBio ClavystBio’s mission is to accelerate the commercialization of life science breakthroughs into health impact.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years. Connect with her at [link].

BioTech 107
article thumbnail

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Digital Health Global

million from Capital Grand Est and MACSF, as well as business angels, to accelerate its development in Europe and the United States. STRASBOURG, France–(BUSINESS WIRE)– BrainTale, a French medtech deciphering white matter to enable better brain care, announces it has gathered € 4.5 Today, the company has gathered €4.5

article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

Both Wellington and Forbion are visionaries and highly experienced biotech investors, and we look forward to working closely with them in our efforts to transform the gene editing landscape.” “Our Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space. With funds totaling more than €1.2

article thumbnail

Turbine Upsizes its Series A Round to €25.5 Million and Appoints Seasoned Independent Directors to its Board

Digital Health Global

These individuals have personally built leading technology platforms supercharging drug development globally. Their buy-in shows that our platform is differentiated and poised to unlock truly novel therapies for currently underserved patient populations through efficient, simulation-guided development. Jane Rhodes, Ph.D.,

BioTech 88
article thumbnail

QuantHealth Announces $15M Series A for its AI Platform That Enhances Success of Clinical Trials

Digital Health Global

QuantHealth bridges these gaps by simulating trials at scale, to expedite, derisk, and optimize drug development. QuantHealth proudly supports several large pharma companies, numerous biotechs, as well as CROs, and other industry partners.

BioTech 88